

**IN THE CLAIMS**

Please amend claims 1, 13, and 17, as indicated below. Please cancel the previously withdrawn, non-elected claims 2-10 without prejudice. Please cancel claims 21-22 without prejudice. Please add new claims 23-24. The following listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended): An isolated marine actinomycete having an obligate requirement of sodium for growth, wherein the marine ~~actinomycete~~ actinomycete is a strain of *Salinospora* comprising [[an]] adenosine at position 207 of a 16S rRNA, [[a]] cytidine at position 366 of the 16S rRNA, [[a]] uridine at position 467 of the 16S rRNA, and [[a]] uridine at position 468 of the 16S rRNA, wherein the position numbers 207, 366, 467, and 468 correspond to the *E. coli* numbering system.

2-12. (Canceled).

13. (Currently Amended): The isolated marine actinomycete of claim 1, further comprising [[an]] guanidine at position 1456 of the 16S rRNA, wherein the position number 1456 corresponds to the *E. coli* numbering system.

14. (Previously presented): The isolated marine actinomycete of claim 1, comprising the nucleotide sequence of SEQ ID NO:5.

15. (Previously presented): The isolated marine actinomycete of claim 1, comprising the nucleotide sequence of SEQ ID NO:3.

16. (Previously presented): The isolated marine actinomycete of claim 1, comprising the nucleotide sequence of SEQ ID NO:4.

17. (Currently amended): The isolated marine actinomycete of claim 1, wherein the marine actinomycete is [[a]] obtained from sediment.

18. (Previously presented): A method for producing a biomolecule, comprising culturing a marine actinomycete of claim 1 in a growth media, wherein the biomolecule is produced by the marine actinomycete;


collecting the marine actinomycete or the growth media containing the biomolecule; and extracting the biomolecule from the marine actinomycete or the growth media, thereby producing the biomolecule.

19. (Previously presented): The method of claim 18, wherein the biomolecule is salinosporamide A.

20. (Previously presented): The method of claim 18, wherein the growth media comprises sodium at a concentration of 450 mM.

21-22. (Canceled).

23. (New): A compound having the structure:



In re Application of:

Fenical et al.

Application No.: 09/991,518

Filed: November 16, 2001

Page 5

PATENT

Attorney Docket No.: UCSD 1630-1

24. (New): A pharmaceutical composition, comprising an effective amount of a pharmaceutically acceptable carrier and a compound having the structure:

